Indeed, the tumor-specific role of T cell expressed TIM-3 as well as potential tumor cell-expressed TIM-3 will need to be clarified in order to rationally design TIM-3 targeted immunotherapy. The gene discussed is HAVCR2; the disease is neoplasm.